Polyclonal antibodies are produced by the immune system in response to antigens injected into the body. The immune system recognizes these antigens as foreign and targets them for clearance. However, a failure to mount an appropriate immune response can result in the addition of an adjuvant. Nevertheless, most antibody production can be traced back to immunization. Moreover, increasing incidence of cancer across the globe is expected to boost the market growth.
According to an article published by Cancer Research UK in 2015, 55,122 new cases of breast cancer were registered in 2015. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4347
The global polyclonal antibody market is estimated to be valued at US$ 943.6 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).
Growing cases of infectious diseases are projected to propel growth of the global polyclonal antibody market.
Growing incidence of infectious diseases such as Ebola virus worldwide, especially in under-developed countries, is projected to drive the market growth during the forecast period. For instance, according to an article published by the World Health Organization (WHO) in February 2020, the outbreak of Ebola virus in West Africa was the largest outbreak during 2014-2016 and it still continues in various countries. The facts and figures are given below:
The development of polyclonal antibodies in North America is projected to drive the market growth
North America is expected to hold leading position in the global polyclonal antibody market due to ongoing research and development in the region. For instance, in August 2018, SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced that its anti-Ebola immunotherapy, SAB-139, offers100% protection against a lethal dose of the Ebola virus in an animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).
Global Polyclonal Antibody Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
Lockdowns in various countries have placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products, and affected growth of healthcare businesses of various companies across the globe.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4347
As a result, the impact of the COVID-19 pandemic is expected to limit growth of the global polyclonal antibody market during the forecast period.
Key Players
Major players operating in the global polyclonal antibody market are Abcam plc, GenScript, Merck KGaA., IgY Immune Technologies & Life Sciences Inc., Thermo Fisher Scientific Inc., Takara Bio Inc., Genway Biotech, Inc., Geno Technology Inc., DC Biosciences Ltd., Good Biotech Corp, Rockland Immunochemicals, Inc., EpiGentek Group Inc., Innovagen AB., and GeneTex, Inc. among others.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4347
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Polyclonal Antibody Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Polyclonal Antibody Industry Impact
Chapter 2 Global Polyclonal Antibody Competition by Types, Applications, and Top Regions and Countries
2.1 Global Polyclonal Antibody (Volume and Value) by Type
2.3 Global Polyclonal Antibody (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Polyclonal Antibody Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Polyclonal Antibody Market Analysis
Chapter 6 East Asia Polyclonal Antibody Market Analysis
Chapter 7 Europe Polyclonal Antibody Market Analysis
Chapter 8 South Asia Polyclonal Antibody Market Analysis
Chapter 9 Southeast Asia Polyclonal Antibody Market Analysis
Chapter 10 Middle East Polyclonal Antibody Market Analysis
Chapter 11 Africa Polyclonal Antibody Market Analysis
Chapter 12 Oceania Polyclonal Antibody Market Analysis
Chapter 13 South America Polyclonal Antibody Market Analysis
Chapter 14 Company Profiles and Key Figures in Polyclonal Antibody Business
Chapter 15 Global Polyclonal Antibody Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
View Press Release: https://www.coherentmarketinsights.com/press-release/polyclonal-antibody-market-3607
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837